caa a22 4500 469121483 CHVBK 20180323133140.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF02246249 doi (NATIONALLICENCE)springer-10.1007/BF02246249 Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III) [Elektronische Daten] A French/Swiss double-blind trial [T. Bougerol, C. Uchida, J. Gachoud, M. Köhler, H. Mikkelsen] The efficacy and tolerability of moclobemide and fluvoxamine, two new types of antidepressant agents, were compared in a multicentre, double-blind prospective study of patients with a diagnosis of major depressive episode (DSM III). Patients were randomized to receive either moclobemide (150 mg) or fluvoxamine (50 mg) twice daily for 7 days, immediately following a washout period of at least 1 week. Dosages were increased where necessary on day 8, to a maximum of moclobemide 450 mg or fluvoxamine 200 mg and in most cases were maintained at these levels for the remainder of the study period (4-6 weeks). Both treatment groups showed a marked antidepressant effect. While both treatments were well tolerated, moclobemide showed a more favourable side-effect profile than fluvoxamine. Of the 126 patients eligible for evaluation, 34 withdrew from therapy, 22% in the moclobemide group and 30% in the fluvoxamine group. Adverse events were reported in 41.8% of patients treated with moclobemide compared to 60.3% of patients in the fluvoxamine group. Reports of dry mouth and other anticholinergic effects were more frequent among those treated with fluvoxamine. A greater number of gastrointestinal complaints, especially nausea, also occurred in the fluvoxamine-treated patients. Springer-Verlag, 1992 Moclobemide nationallicence MAOI nationallicence RIMA nationallicence Fluvoxamine nationallicence 5-HT reuptake inhibitor nationallicence Depression nationallicence Bougerol T. Service Hospitalo-Universitaire de Psychiatrie d'Adultes, (Pr Scotto) Hôpital Sainte-Marguerite, 270 Boulevard de Sainte Marguerite, F-13274, Marseille Cedex 9, France aut Uchida C. Pharma Division, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Gachoud J. Pharma Switzerland, F. Hoffmann-La Roche Ltd, CH-4142, Münchenstein, Switzerland aut Köhler M. Pharma Division, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Mikkelsen H. Pharma Division, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Psychopharmacology Springer-Verlag 106(1992-02-01), S102-S108 0033-3158 106<S102 1992 106 213 https://doi.org/10.1007/BF02246249 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02246249 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bougerol T. Service Hospitalo-Universitaire de Psychiatrie d'Adultes, (Pr Scotto) Hôpital Sainte-Marguerite, 270 Boulevard de Sainte Marguerite, F-13274, Marseille Cedex 9, France aut NATIONALLICENCE 700 1- Uchida C. Pharma Division, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Gachoud J. Pharma Switzerland, F. Hoffmann-La Roche Ltd, CH-4142, Münchenstein, Switzerland aut NATIONALLICENCE 700 1- Köhler M. Pharma Division, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Mikkelsen H. Pharma Division, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106(1992-02-01), S102-S108 0033-3158 106<S102 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer